[O3-5] SARS2-7

[O3-5-1] Structural basis for the recognition of SARS-CoV-2 spike by potent neutralizing antibody NT-108

*Yuki Anraku¹, Taishi Onodera², Shunsuke Kita¹, Yu Adachi², Saya Moriyama², Akihiko Sato^3,4, Takao Nomura¹, Takashi Tadokoro^1,5, Kohei Yumoto^1,2, Shiori Ito¹, Cong Tian¹, Hideo Fukuhara^1,3, Michihito Sasaki³, Yasuko Orba³, Nozomi Shiwa², Naoko Iwata², Noriyo Nagata², Tateki Suzuki⁶, Jiei Sasaki⁶, Tsuyoshi Sekizuka², Keisuke Tonouchi², Shuetsu Fukushi², Hiroyuki Satofuka⁷, Yasuhiro Kazuki⁷, Lin Sun², Mitsuo Oshimura⁸, Makoto Kuroda², Tadaki Suzuki², Hirofumi Sawa³, Takao Hashiguchi⁶, Yoshimasa Takahashi², Katsumi Maenaka¹ (1. Faculty of Pharmaceutical Sciences, Hokkaido University, 2. National Institute of Infectious Diseases, 3. Division of Molecular Pathobiology, Research Center for Zoonosis Control, 4. Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., 5. Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 6. Institute for Frontier Life and Medical Sciences, Kyoto University, 7. Chromosome Engineering Research Center, Tottori University, 8. Trans Chromosomics Inc.)